NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Fokas, Emmanouil ^a   Yoshimura, Michio ^a   Prevo, Remko ^a   Higgins, Geoff ^a   Hackl, Wolfgang ^b   Maira, Sauveur Michel ^b   Bernhard, Eric J ^a   McKenna, W Gillies ^a   Muschel, Ruth J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Endothelial cells; MTOR; PI3K; Radiosensitization; VEGF

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NVP BGT 226; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG; 8 (6 METHOXYPYRIDIN 3 YL) 3 METHYL 1 (4 PIPERAZIN 1 YL 3 TRIFLUOROMETHYLPHENYL) 1,3 DIHYDROIMIDAZO(4,5 C)QUINOLIN 2 ONE; 8-(6-METHOXYPYRIDIN-3-YL)-3-METHYL-1-(4-PIPERAZIN-1-YL-3-TRIFLUOROMETHYLPHENYL)-1,3-DIHYDROIMIDAZO(4,5-C)QUINOLIN-2-ONE; IMIDAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; RADIOSENSITIZING AGENT; TARGET OF RAPAMYCIN KINASE;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE; CLONOGENESIS; ENDOTHELIUM CELL; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPOPHARYNX CANCER; IN VITRO STUDY; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; DRUG ANTAGONISM; DRUG EFFECT; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

CELL LINE, TUMOR; ENDOTHELIAL CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMIDAZOLES; PHOSPHATIDYLINOSITOL 3-KINASES; QUINOLINES; RADIATION-SENSITIZING AGENTS; TOR SERINE-THREONINE KINASES;

EID: 84858857598     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-48     Document Type: Article

References (36)

1. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011, 11:239-253. 10.1038/nrc3007, 21430696.
2. Maity A, Bernhard EJ. Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy. Cancer Res 2010, 70:2141-2145. 10.1158/0008-5472.CAN-09-3615, 2840203, 20179191.
3. McKenna WG, Muschel RJ, Gupta AK, Hahn SM, Bernhard EJ. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 2003, 22:5866-5875. 10.1038/sj.onc.1206699, 12947393.
4. Bernhard EJ, Stanbridge EJ, Gupta S, Gupta AK, Soto D, Bakanauskas VJ, Cerniglia GJ, Muschel RJ, McKenna WG. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res 2000, 60:6597-6600.
5. Gupta AK, Bakanauskas VJ, Cerniglia GJ, Cheng Y, Bernhard EJ, Muschel RJ, McKenna WG. The Ras radiation resistance pathway. Cancer Res 2001, 61:4278-4282.
6. Kim IA, Fernandes AT, Gupta AK, McKenna WG, Bernhard EJ. The influence of Ras pathway signaling on tumor radiosensitivity. Cancer Metastasis Rev 2004, 23:227-236.
7. Prevo R, Deutsch E, Sampson O, Diplexcito J, Cengel K, Harper J, O'Neill P, McKenna WG, Patel S, Bernhard EJ. Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res 2008, 68:5915-5923. 10.1158/0008-5472.CAN-08-0757, 18632646.
8. Rudner J, Ruiner CE, Handrick R, Eibl HJ, Belka C, Jendrossek V. The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiat Oncol 2010, 5:108. 10.1186/1748-717X-5-108, 2998511, 21080918.
9. Cengel KA, Voong KR, Chandrasekaran S, Maggiorella L, Brunner TB, Stanbridge E, Kao GD, McKenna WG, Bernhard EJ. Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. Neoplasia 2007, 9:341-348. 10.1593/neo.06823, 1854847, 17460778.
10. Brunner TB, Cengel KA, Hahn SM, Wu J, Fraker DL, McKenna WG, Bernhard EJ. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras. Cancer Res 2005, 65:8433-8441. 10.1158/0008-5472.CAN-05-0158, 16166322.
11. Li HF, Kim JS, Waldman T. Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol 2009, 4:43. 10.1186/1748-717X-4-43, 2765447, 19828040.
12. McKenna WG, Muschel RJ, Gupta AK, Hahn SM, Bernhard EJ. Farnesyltransferase inhibitors as radiation sensitizers. Semin Radiat Oncol 2002, 12:27-32. 10.1053/srao.2002.34866, 12174342.
13. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578. 10.1056/NEJMoa053422, 16467544.
14. Seeliger H, Guba M, Kleespies A, Jauch KW, Bruns CJ. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 2007, 26:611-621. 10.1007/s10555-007-9077-8, 17713840.
15. Manegold PC, Paringer C, Kulka U, Krimmel K, Eichhorn ME, Wilkowski R, Jauch KW, Guba M, Bruns CJ. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res 2008, 14:892-900. 10.1158/1078-0432.CCR-07-0955, 18245553.
16. Shinohara ET, Cao C, Niermann K, Mu Y, Zeng F, Hallahan DE, Lu B. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 2005, 24:5414-5422. 10.1038/sj.onc.1208715, 15940265.
17. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008, 118:3065-3074. 2518073, 18725988.
18. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008, 7:1851-1863. 10.1158/1535-7163.MCT-08-0017, 18606717.
19. Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S, Mier JW. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 2010, 16:3628-3638. 10.1158/1078-0432.CCR-09-3022, 2905505, 20606035.
20. Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, Golec JM, Pollard JR. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol 2011, 7:428-430.
21. Abid MR, Guo S, Minami T, Spokes KC, Ueki K, Skurk C, Walsh K, Aird WC. Vascular endothelial growth factor activates PI3K/Akt/forkhead signaling in endothelial cells. Arterioscler Thromb Vasc Biol 2004, 24:294-300.
22. Kim DW, Huamani J, Fu A, Hallahan DE. Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy. Int J Radiat Oncol Biol Phys 2006, 64:38-46. 10.1016/j.ijrobp.2005.02.008, 16377414.
23. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000, 60:2178-2189.
24. Pore N, Gupta AK, Cerniglia GJ, Jiang Z, Bernhard EJ, Evans SM, Koch CJ, Hahn SM, Maity A. Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Res 2006, 66:9252-9259. 10.1158/0008-5472.CAN-06-1239, 16982770.
25. Wang X, Yue P, Chan CB, Ye K, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Fu H, Khuri FR, Sun SY. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol 2007, 27:7405-7413. 10.1128/MCB.00760-07, 2169067, 17724079.
26. Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, Garcia-Echevrria C, Yung WK. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 2009, 8:2204-2210. 10.1158/1535-7163.MCT-09-0160, 2752877, 19671762.
27. Marone R, Erhart D, Mertz AC, Bohnacker T, Schnell C, Cmiljanovic V, Stauffer F, Garcia-Echeverria C, Giese B, Maira SM, Wymann MP. Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol Cancer Res 2009, 7:601-613. 10.1158/1541-7786.MCR-08-0366, 19372588.
28. Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM, Garcia-Echeverria C, Mercuri M, et al. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 2010, 16:530-540. 10.1158/1078-0432.CCR-09-0816, 20068094.
29. Konstantinidou G, Bey EA, Rabellino A, Schuster K, Maira MS, Gazdar AF, Amici A, Boothman DA, Scaglioni PP. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res 2009, 69:7644-7652. 10.1158/0008-5472.CAN-09-0823, 2760010, 19789349.
30. Chiarini F, Grimaldi C, Ricci F, Tazzari PL, Evangelisti C, Ognibene A, Battistelli M, Falcieri E, Melchionda F, Pession A, et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 2010, 70:8097-8107. 10.1158/0008-5472.CAN-10-1814, 20876803.
31. Vispe S, Cazaux C, Lesca C, Defais M. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res 1998, 26:2859-2864. 10.1093/nar/26.12.2859, 147643, 9611228.
32. Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, Sun J, Monahan-Earley RA, Shiojima I, Nagy JA, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006, 10:159-170. 10.1016/j.ccr.2006.07.003, 2531257, 16904613.
33. Dayanir V, Meyer RD, Lashkari K, Rahimi N. Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation. J Biol Chem 2001, 276:17686-17692. 10.1074/jbc.M009128200, 11278468.
34. Sun JF, Phung T, Shiojima I, Felske T, Upalakalin JN, Feng D, Kornaga T, Dor T, Dvorak AM, Walsh K, Benjamin LE. Microvascular patterning is controlled by fine-tuning the Akt signal. Proc Natl Acad Sci USA 2005, 102:128-133. 10.1073/pnas.0403198102, 538747, 15611473.
35. Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, Henley A, Di-Stefano F, Ahmad Z, Guillard S, et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007, 67:5840-5850. 10.1158/0008-5472.CAN-06-4615, 17575152.
36. Fokas E, Im JH, Hill S, Yameen S, Stratford M, Beech J, Hackl W, Maira SM, Bernhard EJ, McKenna WG, Muschel RJ. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res 2012, 72:239-248. 10.1158/0008-5472.CAN-11-2263, 22108822.